{
  "id": 10544015,
  "title": "Regulator-mandated study finds no link between semaglutide use and pancreatic cancer",
  "url": "https://urgent.news/2026/09/28/regulator-mandated-study-finds-no-link-between-semaglutide-use-and",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T22:00:21.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-mandated-link-semaglutide-pancreatic-cancer.html"
  },
  "original_language": "en",
  "account": "A recent study presented at the European Association for the Study of Diabetes conference in Milan, Italy, found no link between the use of semaglutide and an increased risk of pancreatic cancer. Semaglutide is a medication used to treat type 2 diabetes and aid in weight management. The study, conducted by researchers from the University of Southern Denmark, analyzed nationwide health registry data from Denmark, Sweden, and Norway.\n\nThe researchers compared new users of semaglutide with matched users of non-incretin antidiabetic drugs, such as sulfonylureas, SGLT-2 inhibitors, or insulin. They found that there was no significant difference in the incidence of pancreatic cancer between the two groups. Among the 97,464 semaglutide users, there were 131 cases of pancreatic cancer, while among the active comparator users, there were 123 cases.\n\nThe pooled estimates showed no increased risk of pancreatic cancer associated with semaglutide use (pooled hazard ratio 0.91, 95% confidence interval 0.71–1.16). No dose-response or dose-duration effects were observed either. The study's results were consistent across countries and remained robust after multiple sensitivity and supplementary analyses. The findings support the conclusion that semaglutide does not increase the risk of pancreatic cancer compared to other glucose-lowering drugs used for type 2 diabetes treatment.",
  "summary": "New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry data from Denmark, Sweden and Norway. The regulator-mandated post-authorization study was presented by Anton Pottegård, a professor at the University of Southern Denmark in…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}